# Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine

> **NCT00805389** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 713 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix-B™
- **BIOLOGICAL:** Fendrix™
- **BIOLOGICAL:** GSK Biologicals' Hepatitis B vaccines (GSK223192A)
- **BIOLOGICAL:** HBsAg (Booster injection)

## Key facts

- **NCT ID:** NCT00805389
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-15
- **Primary completion:** 2010-09-29
- **Final completion:** 2011-07-14
- **Target enrollment:** 713 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00805389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00805389, "Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00805389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*